J P Morgan Chase & Co Reiterates “GBX 4,500” Price Target for AstraZeneca plc (AZN)

J P Morgan Chase & Co set a GBX 4,500 ($59.79) target price on AstraZeneca plc (LON:AZN) in a research report report published on Wednesday morning. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on AZN. Morgan Stanley reaffirmed an overweight rating and set a GBX 5,600 ($74.41) price target on shares of AstraZeneca plc in a report on Friday, June 23rd. UBS AG set a GBX 5,150 ($68.43) price target on shares of AstraZeneca plc and gave the company a neutral rating in a report on Tuesday, June 27th. Shore Capital reaffirmed a hold rating on shares of AstraZeneca plc in a report on Wednesday, June 21st. Kepler Capital Markets reaffirmed a buy rating and set a GBX 5,500 ($73.08) price target on shares of AstraZeneca plc in a report on Thursday, July 13th. Finally, Liberum Capital reaffirmed a buy rating and set a GBX 5,500 ($73.08) price target on shares of AstraZeneca plc in a report on Thursday, July 13th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of GBX 5,172.64 ($68.73).

AstraZeneca plc (LON AZN) opened at 5162.00 on Wednesday. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00. The stock’s market capitalization is GBX 65.35 billion. The firm has a 50-day moving average of GBX 4,923.51 and a 200-day moving average of GBX 4,914.37.

ILLEGAL ACTIVITY WARNING: This article was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.truebluetribune.com/2017/10/21/j-p-morgan-chase-co-reiterates-gbx-4500-price-target-for-astrazeneca-plc-azn.html.

In related news, insider Nazneen Rahman acquired 39 shares of AstraZeneca plc stock in a transaction dated Thursday, July 27th. The shares were purchased at an average price of GBX 4,370 ($58.07) per share, for a total transaction of £1,704.30 ($2,264.55).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply